These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32008423)

  • 41. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmaceutical patent law: the Canadian perspective.
    Aumand L; Norman J
    Pharm Pat Anal; 2016 Jul; 5(4):271-9. PubMed ID: 27346187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Review on the Main Phytoconstituents, Traditional Uses, Inventions, and Patent Literature of Gum Arabic Emphasizing
    Ashour MA; Fatima W; Imran M; Ghoneim MM; Alshehri S; Shakeel F
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35208961
    [No Abstract]   [Full Text] [Related]  

  • 45. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
    Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH
    Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanotechnology and Protection of Intellectual Property: Emerging Trends.
    Siri JGS; Fernando CAN; De Silva SNT
    Recent Pat Nanotechnol; 2020; 14(4):307-327. PubMed ID: 32532198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
    Rai AK
    Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cross-specialty developments: a summary of the mutually relevant recent literature from the journal of plastic, reconstructive and aesthetic surgery.
    Glass GE; Mosahebi A; Shakib K
    Br J Oral Maxillofac Surg; 2016 Jan; 54(1):13-21. PubMed ID: 26628201
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative Analysis of Technological Innovation in Knee Arthroplasty: Using Patent and Publication Metrics to Identify Developments and Trends.
    Dalton DM; Burke TP; Kelly EG; Curtin PD
    J Arthroplasty; 2016 Jun; 31(6):1366-1372. PubMed ID: 26787011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 51. Exploring drug patent linkage and the first ANDA litigation in China.
    Han W
    Expert Opin Ther Pat; 2022 Nov; 32(11):1123-1129. PubMed ID: 36354091
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent developments in medicine and law.
    Wojtylak MA; Cebeci BO; Gross SH; Tang CK; Vanderpool D
    Tort Trial Insur Pract Law J; 2003; 38(2):549-83. PubMed ID: 12812222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patent protection strategies.
    Gupta H; Kumar S; Roy SK; Gaud RS
    J Pharm Bioallied Sci; 2010 Jan; 2(1):2-7. PubMed ID: 21814422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patenting trends by Mexican pharmaceutical companies.
    Villafaña-Diaz L; Perez-Garcia JC; Barron-Villaverde D; Perez-Santos M
    Pharm Pat Anal; 2023 Nov; 12(6):275-286. PubMed ID: 38197381
    [No Abstract]   [Full Text] [Related]  

  • 55. Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry.
    Song CH; Han JW
    Springerplus; 2016; 5(1):692. PubMed ID: 27347468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AI-driven molecular generation of not-patented pharmaceutical compounds using world open patent data.
    Shimizu Y; Ohta M; Ishida S; Terayama K; Osawa M; Honma T; Ikeda K
    J Cheminform; 2023 Dec; 15(1):120. PubMed ID: 38093324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Continuing progress in the field of two-dimensional correlation spectroscopy (2D-COS), part II. Recent noteworthy developments.
    Park Y; Jin S; Noda I; Jung YM
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 Jan; 284():121750. PubMed ID: 36030669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patent issues in drug development: perspectives of a pharmaceutical scientist-attorney.
    Melethil S
    AAPS J; 2005 Oct; 7(3):E723-8. PubMed ID: 16353948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis on patents of health care products with substances of medicine food homology in China.
    Liu H; Wang Y; Huang J; Dong Z; Xiao P
    Chin Herb Med; 2024 Jul; 16(3):412-421. PubMed ID: 39072202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-U.S. Free Trade Agreement in Korea.
    Son KB; Bae S; Lee TJ
    Int J Health Serv; 2019 Apr; 49(2):306-321. PubMed ID: 30626258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.